The Trump administration announced new Medicaid drug pricing agreements with nine mid-sized biotechnology and pharmaceutical companies on August 31, including UCB SA, Bridgebio Pharma, and Sun Pharmaceutical. The administration stated all negotiated drugs will be priced at the lowest available rates.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.
The Trump administration on Monday announced new Medicaid drug pricing agreements with nine mid-sized biotechnology and pharmaceutical companies. Every drug “will be at the lowest prices available anywhere in the world,” President Trump said in the Oval Office, surrounded by company executives. Under the agreements, the companies will charge state Medicaid programs the same...